Investigation of tolerablity & effectiveness of Bromocriptine in comparison with Teneligliptin in patients diagnosed with type II diabetes mellitus
Not Applicable
- Conditions
- Health Condition 1: null- type 2 diabetes mellitusHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2018/05/013591
- Lead Sponsor
- asrin Nisha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Newly diagnosed type 2 DM
FBS between 140 mg/dl and 240 mg/dl
PPBS between 200 mg/dl and 350 mg/dl
Hb1Ac between 7% &10%
BMI between 22 and 40 kg/m2
Exclusion Criteria
Patients with complications of DM
Pregnant & nursing women
Patients with known hypersensitivity to Bromocriptine or ergot related compounds or Teneligliptin.
Patients with migraine.
Patients with H/O significant systemic disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method